TCGA-91-6831-01A-11R-1858-07
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 66
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.530
- G2M_CHECKPOINT+0.500
- MYC_TARGETS_V1+0.420
- MYC_TARGETS_V2+0.390
- OXIDATIVE_PHOSPHORYLATION+0.370
- UNFOLDED_PROTEIN_RESPONSE+0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- MITOTIC_SPINDLE+0.290
- TGF_BETA_SIGNALING+0.270
- DNA_REPAIR+0.250
Top 10 suppressed
- P53_PATHWAY-0.340
- APICAL_SURFACE-0.320
- KRAS_SIGNALING_DN-0.310
- TNFA_SIGNALING_VIA_NFKB-0.300
- XENOBIOTIC_METABOLISM-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.280
- INTERFERON_ALPHA_RESPONSE-0.240
- HEDGEHOG_SIGNALING-0.210
- IL2_STAT5_SIGNALING-0.210
- IL6_JAK_STAT3_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C6A16A8F-0AB7-42E9-A068-15EECF2912D3 | — | — | 0.839 |
| 2 | TCGA-85-6560-01A-11R-1820-07 | — | cohortMD1 | 0.833 |
| 3 | BS_V72H4RQS | medulloblastoma | — | 0.822 |
| 4 | MDT-AP-0164 | Med | Medulloblastoma | 0.815 |
| 5 | SRR934990 | — | — | 0.813 |
| 6 | MNG1194 | — | — | 0.812 |
| 7 | SJEPD030795_D3.RNA-Seq | EPN | Posterior Fossa EPN | 0.807 |
| 8 | BS_R5SNFB5B | high-grade glioma | — | 0.806 |
| 9 | MNG1168 | — | — | 0.804 |
| 10 | TCGA-XF-AAN7-01A-11R-A42T-07 | — | — | 0.800 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.420 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.390 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.370 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.310 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.290 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.190 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.060 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.060 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.050 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.050 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.020 | Inavolisib | — uncovered |